Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Series D brings in $43mm for Avedro

Executive Summary

Ophthalmic device and drug developer Avedro Inc. has raised $43mm through its Series D venture round led by Abingworth. Third Point also made a significant investment, and was joined by existing shareholders Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Venture Partners, Borealis Ventures, and Echelon Ventures. Abingworth and Third Point will gain representation on Avedro’s board. The company will use the proceeds for R&D activities involving corneal crosslinking (for cataract and refractive surgery), to gain US approval for future products, and for global commercialization.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Laser
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register